MELITRACEN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H25N
Molecular Weight	291.4299
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCC=C1C2=C(C=CC=C2)C(C)(C)C3=C1C=CC=C3

InChI

InChIKey=GWWLWDURRGNSRS-UHFFFAOYSA-N

InChI=1S/C21H25N/c1-21(2)19-13-7-5-10-17(19)16(12-9-15-22(3)4)18-11-6-8-14-20(18)21/h5-8,10-14H,9,15H2,1-4H3

HIDE SMILES / InChI

Description
Sources: http://buddymd.com/side-effects-deanxit-flupentixol-melitracen
Curator's Comment: Description was created based on several sources, including https://www.aci-bd.com/Brand/Adelax.pdf and https://www.ncbi.nlm.nih.gov/pubmed/18331614

Melitracen (HCl) is a tricyclic antidepressant with actions and effects similar to amitriptyline.Melitracen (HCl) is given orally in the treatment of depression. It should be withdrawn gradually to reduce the risk of withdrawl symptoms. Melitracen (HCl) is primarily indicated in conditions like Anxiety, Asthenia, Depression, gastro-intestinal disorders associated with anxiety and agitation. Melitracen is marketed in Europe and Japan by Lundbeck and Takeda, respectively, for the treatment of depression and anxiety. In addition to single drug preparations, it is also available as Deanxit, a combination product containing both melitracen and flupentixol. The way this drug works hasn’t been thoroughly researched, but some hypothesize that it may work similarly to the drugs Imipramine and Amitriptyline. In comparison to older TCAs, this drug is thought to work more quickly with more favorable side effects.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Anxiety 267 Sources: http://www.papaloizou.com/PublicDocsPDF/SPCs/Deanxit_SPC.pdf	Primary	Approved 8429	Deanxit Approved Use Anxiety − Depression − Asthenia. Neurasthenia, Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts. Launch Date 8.8361278E11
Depression 235 Sources: http://www.mims.com/thailand/drug/info/deanxit/?type=full#Indications	Primary	Approved 8429	Deanxit Approved Use Anxiety − Depression − Asthenia. Neurasthenia, Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts. Launch Date 8.8361278E11
Asthenia 4 Sources: http://www.papaloizou.com/PublicDocsPDF/SPCs/Deanxit_SPC.pdf	Primary	Approved 8429	Deanxit Approved Use Anxiety − Depression − Asthenia. Neurasthenia, Psychogenic depression. Depressive neuroses. Masked depression. Psychosomatic affections accompanied by anxiety and apathy. Menopausal depressions. Dysphoria and depression in alcoholics and drug-addicts. Launch Date 8.8361278E11

PubMed

Title	Date	PubMed
Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis.	2005 Dec 9	16314157
Purple urine bag syndrome in nursing homes: ten elderly case reports and a literature review.	2008	19281065
Clinical trial: a randomized controlled cross-over study of flupenthixol + melitracen in functional dyspepsia.	2008 Jun 1	18331614
Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry.	2009 Nov	18839201

Patents

Sample Use Guides

In Vivo Use Guide

Oral Depression Adult: Initially, 25 mg bid-tid, gradually increased to 225 mg daily if necessary. Elderly: Initially, 25 mg daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

MELITRACEN

Official Name

English

1-PROPANAMINE, 3-(10,10-DIMETHYL-9(10H)-ANTHRACENYLIDENE)-N,N-DIMETHYL-

Systematic Name

English

ADELAX

Brand Name

English

melitracen [INN]

Common Name

English

MELITRACEN [MI]

Common Name

English

Melitracen [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QN06CA02